Biomedical subjects

V N Glozman

Publications and source records attributed to V N Glozman.

At least 19 recordsLinked to original sources

PubMed1991

[Use of mildronate in therapy of seroresistant syphilis (serologic and immunologic comparisons].

Clinico-serological and immunological examinations were applied to 84 patients suffering from seroresistant syphilis with positive serological reactions within 1.5 to 10 years after termination of the treatment by various methods. The initial diagnosis of recently inflicted secondary syphilis was recorded in 8.9 per cent of the patients. 43.3 and 47.8 per cent of the patients had secondary relapsing syphilis and early occult syphilis, respectively. The percentage of lymphocytes CD3+, CD4+, CD8+ and HLA DR+ was determined in peripheric blood with the monoclonal antibodies OKT-3+, OKT-4+, OKT-8+ and FITC-labeled antimouse Ig. The quantity of IgA, IgG and IgM was determined by radial immunodiffusion. The immunoregulatory index (IRI, the ratio of T-helper/inductor cells and T-suppressor cells/cytotoxics) was calculated. The use of mildronate, a drug developed at the Institute of Organic Chemistry of the Academy of Sciences of the Latvian SSR (Riga), led to normalization of the impaired immunological indices and complete negativation of the serological reactions in the group of the patients with disorders in the immunity status (CD8+ - 33 per cent and IRI - 1.3), p less than 0.01.

Adult↗

PubMed1990

[The assessment of the efficacy of introducing a new method for treating gonorrhea].

Proteolytic enzymes (chymotrypsin, trypsin) i.m. injections in a dose of 5 mg twice daily for 4 to 10 days were used in combined therapy of 218 patients with recurrences of gonorrhea, gonorrheal epididymitis and orchiepididymitis; 23 patients with acute orchiepididymitis were injected heparin intramuscularly in a dose of 5000 U twice daily for 7 weeks. Etiologic cure was achieved in 99.7 percent, postgonorrheal residual phenomena were detected in 5.7 percent of cases (93.9 and 17.5 percent, respectively, in a reference group). The length of treatment of a patient with gonorrhea relapse shortened by 8.6 days on an average and of that with orchiepididymitis and epididymitis by 5.9 days. Formula are presented for calculating the economic efficacy of treatment of those working and not working patients.

Anti-Bacterial Agents↗

PubMed1990

[Recurrences of gonorrhea in men (the characteristics of the course and treatment)].

The examination has involved 218 patients. The incidence of relapses in acute and subacute gonorrhea has made up 6.3%, 5.2% in chronic and 4.5% in complicated condition. Recurrences were observed in 5.3 days on an average after therapy of new gonorrhea cases and in 8.8 days after treatment of chronic disease. Mixed urogenital infection was recorded in 37.8% of cases; in gonorrhea eventuating in clinical cure it was observed in 24% of cases. Relapses developed in 50.2% of patients after antibiotic therapy and in 49.8% after combined treatment. A single relapse occurred in 85.6% of patients; two and more relapses in 14.4%. The disease recurred after penicillin therapy in 6.5% after aminoglycosides in 6.9%, and after tetracyclin treatment in 4.2% of cases. Therapy with proteolytic enzymes (chymotrypsin, trypsin 5 mg i.m. twice a day) combined with antibiotics resulted in etiological cure in 99.3% of patients, the incidence of postgonorrheal symptoms reduced and made up 6.8% (in the patients not administered protease this share made up 19.2%), and the length of inpatient treatment shortened by 8-14.6 days.

Adult↗

PubMed1990

[The sociomedical efficacy of the enzyme therapy of gonorrhea patients].

The study has involved 3702 male patients with gonorrhea. Of these 62 percent were fresh cases, 38 percent chronic ones; there were 218 patients (5.9 percent) with recurrences, of these 63.3 percent with new relapses and 36.7 percent with chronic ones. 85.3 percent of patients developed monorelapses. The recurrences were equally frequent after antibiotic therapy (50.2 percent) and after combined treatment (49.8 percent). Proteolytic enzymes (chymotrypsin, trapsin 5 mg twice daily with a 12 hrs interval) in combination with an antibiotic were administered to 242 patients with gonorrhea complicated by epididymo-orchitis and with gonorrhea relapses. Etiologic cure was achieved in all of them; postgonorrheal conditions were recorded in 6-7 percent and depended on the antibiotic administered; in reference patients recurrences were recorded in 4.2-6.5 percent of cases, postgonorrheal conditions in 14-21.4 percent of cases. Enzymic therapy helped reduce the length of inpatient therapy of a patient by 5.93 days on an average in cases with orchidoepididymitis and by 14.64 days in gonorrhea relapses, with the economic effect per worker being 131.4 and 307.2 rubles, respectively.

Anti-Bacterial Agents↗

PubMed1990

[A comparative evaluation of antibiotic-enzyme therapy and of generally accepted methods for treating gonorrhea patients].

The authors analyze the immunity-correcting effect of antibiotic and enzyme therapy in 32 patients with gonorrheal orchidoepididymitis and 31 with gonorrhea relapses and compare it to the results of routine therapy in 60 patients with chronic and complicated gonorrhea. They come to a conclusion that combined administration of proteolytic enzymes and antibiotics more effectively corrects a number of disordered immunity nonspecific defense parameters (blood serum levels of circulating immune complexes and lysozyme).

Anti-Bacterial Agents↗

PubMed1990

[Immunologic foundation of enzyme therapy of patients with orchiepididymitis].

Twenty eight patients aged 18 to 40 years with urogenital infections complicated by orchiepididymitis were examined immunologically. The use of specific monoclonal antibodies OKT-4+ and OKT-8 revealed lower contents of T-helper cells (Thc) (23.33 +/- 9.7%) and higher contents of T-suppressor cells (Tsc) (41.17 +/- 13.41%) in them as compared to those in healthy volunteers (18 persons) and patients with noncomplicated urogenital infections (19 persons). There was a significant decrease in the immunoregulatory index (IRI): Thc/Tsc (0.68 +/- 0.33) reached in some patients the ratio observed in persons infected with the HIV (0.6 +/- 0.2) and an increase in the contents of circulating immune complexes (CIC) (28.5 +/- 2.0 arbitrary units against the normal of 10.0 +/- 0.7). Enzyme therapy including the use of chymotrypsin and trypsin manufactured in the USSR in doses of 10 mg each administered intramuscularly once a day or in doses of 5 mg each administered intramuscularly twice a day for 10 days promoted normalization of the impaired immunity indices (Thc 44.0 +/- 10.51%, Tsc 31.5 +/- 11.26%, IRI 1.53 +/- 0.33 and CIC 12.1 +/- 0.74 arbitrary units). Therefore, the enzymes had an immunomodulating effect. It is likely that they will be useful in treatment of infectious inflammatory processes accompanied by analogous immune disorders which makes the enzyme immunocorrection more applicable in treatment of various pathological processes.

Adolescent↗

PubMed1990

[The prevention of pathospermia in patients with orchiepididymitis].

Spermatopathy persisting for a long time after therapy was detected in 48-60 per cent of the patients with gonorrheal orchiepididymitis. Intramuscular chymotrypsin, a proteolytic enzyme, in a dose of 2 mg twice daily (every 12 hrs) for 6-10 days, combined with an antibiotic, essentially (to 14.3-16.6 per cent) reduced the incidence rate of spermatogenesis disorders and alleviated the severity of these disorders vs. the patients treated with conventional therapy.

Adult↗

PubMed1989

[Improvement in treatment of patients with gonorrheal epididymo-orchitis].

Examinations of 46 patients with gonorrheal orchiepididymitis have revealed reduced IgA, IgG and IgM levels, a rise of circulating immune complexes level, and depressed lysozyme activity. Addition of proteolytic enzymes to combined therapy has improved the treatment efficacy and normalized the humoral immunity and nonspecific defense parameters.

Adolescent↗

PubMed1989

[Criteria of recovery from gonorrhea].

A total of 563 case histories of gonorrhea patients and 218 ones of patients with gonorrhea recurrences are analyzed. 86.7-87.5% of recurrences were recorded in the first week after treatment for acute or chronic condition (before the provocation test). The relapses develop earlier after the treatment for acute or subacute gonorrhea than for the chronic condition, and are most common between the third and seventh days after therapy. The share of patients timely consulting the doctors is in inverse proportion with the time of the check-ups (the criterion of cure being 96.2%, the first control 84.1%, the second one 62%). The validity of cure should better be checked up on the fifth-sixth days after therapy, and not on days 7-10. Patients with complicated urogenital diseases (prostatitis, orchiepididymitis, infiltrative urethritis) should be followed up after the first check-up.

Acute Disease↗

PubMed1988